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Objective: The VIRTUE Registry describes the mid-term clinical and
morphological results of thoracic endovascular repair (TEVR) in patients
with type B aortic dissection.
Methods: This was a prospective cohort study. The VIRTUE Regis-
try is a prospective, multicentre clinical trial that enrolled patients with
complicated acute (<15 days), subacute (15e92 days), and chronic (>92
days) type B aortic dissections treated with the Valiant endograft. One hun-
dred patients were enrolled and the clinical outcomes described at the 3-
year follow-up. Analysis of the aortic area and false lumen thrombosis rates
deﬁned the morphological response to TEVR in the three clinical groups.
Results: Three-year all-cause mortality (18%, 4%, and 24%), dissection
related mortality (12%, 4%, and 9%), aortic rupture (2%, 0%, and 4%), retro-
grade type A dissection (5%, 0%, and 0%), and aortic reintervention rates
(20%, 22%, and 39%) were, respectively, deﬁned for patients with acute
(n = 50), subacute (n = 24), and chronic (n = 26) dissections. Analysis of
aortic morphology observed that patients with subacute dissection demon-
strated a similar degree of aortic remodelling to patients with acute dissec-
tion. Patients with acute and subacute dissection exhibited greater aortic
plasticity than patients with chronic dissection.
Conclusions: The principle clinical ﬁndings suggest that TEVR is able
to provide good protection from aortic-related death in the mid-term,
but with a high rate of aortic reintervention. Analysis of aortic morphology
suggested that aortic remodelling in subacute patients is similar to the acute
group. Retention of aortic plasticity in the subacute group lengthens
the therapeutic window for the treatment of uncomplicated type B
dissection.
Inﬂuence of Cardiovascular Risk Factors on Levels of Matrix
Metalloproteinases 2 and 9 in Human Abdominal Aortic Aneurysms
Dilmé J.-F., Bellmunt S., Camacho M., Solà-Villà D., Romero J.-M.,
Escudero J.-R., Vila L. Eur J Vasc Endovasc Surg 2014;48:372-9.
Objective: To evaluate the inﬂuence of cardiovascular risk factors on
levels of matrix metalloproteinases (MMP) 2 and 9 in human abdominal
aortic aneurysms (AAA).
Methods: Aortic samples were collected from patients who under-
went AAA repair (n = 89). Patients were stratiﬁed according to the
maximum transverse aorta diameter: small diameter (<55 mm), moderate
diameter (55e69.9 mm) and large diameter ($70 mm). Aortic walls
were studied using real-time PCR and immunohistochemistry. MMP-2,
MMP-9, a-actin, CD45, and CD68 transcript levels were determined rela-
tive to b-actin. Quantitative data were expressed as median (IQ-range).
Results: No differences were found in MMP-2 expression between
the patient groups, which was mainly associated with vascular smooth
muscle cells (VSMC); however, MMP-9 displayed the maximum level in
the moderate-diameter group, associated with inﬁltrating macrophages.
Current smoking (CS) and renal insufﬁciency (RI) signiﬁcantly increased
local levels of MMP-2 (CS 349.5 [219.5e414.1] vs. no-CS 184.4
[100.0e320.5]; p < .008; RI 286.8 [189.6e410.8] vs. no-RI 177.3
[99.3e326.9]; p = .047). Nevertheless, after stepwise linear regression anal-
ysis only CS remained as an independent variable predicting local levels of
MMP-2 (p = .002). No risk factors inﬂuenced local levels of MMP-9.
Conclusions: The results show that local levels of MMP-2, an impor-
tant factor for AAA development, were increased in current smoking AAA
patients. MMP-2 was mainly associated with VSMC. It is suggested that
MMP-2 could contribute signiﬁcantly to the increased AAA growth rate
observed in current smoking patients. These ﬁndings support inclusion of
smokers in screening for aneurysmal disease, and emphasize the need for
more aggressive monitoring of aneurysmal disease outside the surgical rangein patients who smoke at the time of diagnosis and in those who continue to
smoke during follow-up.
Type II Endoleak: Conservative Management Is a Safe Strategy
Sidloff D.A., Gokani V., Stather P.W., Choke E., Bown M.J., Sayers R.D.
Eur J Vasc Endovasc Surg 2014;48:389-97.
Objective: Type II endoleak is the most common complication after
endovascular abdominal aortic aneurysm repair (EVAR); however, its natu-
ral history is unclear. The aim of this study was to examine the incidence and
outcomes of type II endoleak, at a single institution after EVAR.
Methods: A total of 904 consecutive patients who underwent EVAR
between September 1995 and July 2013 at a single centre were entered
onto a prospective database. All patients were followed up by duplex ultra-
sound (DUSS). Patients who developed type II endoleak were compared for
preoperative demographics, mortality, and sac expansion.
Results: A total of 175(19%) patients developed type II endoleak
over a median follow-up of 3.6 years (1.5e5.9 years); 54% of type II
endoleaks spontaneously resolved within 6 months (0.25e1.2 years).
No difference was found in preoperative demographics or choice of
endograft between the two groups. Survival was signiﬁcantly higher in
the group with type II endoleak (94.1% vs 85.6%; p = .01) and this effect
was most pronounced in those with late type II endoleaks (97.7% vs.
85.6% p = .004). No difference was seen in aneurysm-related mortality
or rate of type I endoleak between the two groups. Freedom from sac
expansion (>5 mm from preoperative diameter) was signiﬁcantly lower
in the group of patients with type II endoleak (82.5% vs. 93.2%, p =
.0001); however, at a threshold of >10 mm from preoperative diameter
no difference was seen.
Conclusions: Patients with isolated type II endoleak demonstrate
equivalent aneurysm-related mortality and an improved survival.
Signiﬁcant Savings with a Stepped Care Model for Treatment of
Patients with Intermittent Claudication
Fokkenrood H.J.P., Scheltinga M.R.M., Koelemay M.J.W., Breek J.C.,
Hasaart F., Vahl A.C., Teijink J.A.W. Eur J Vasc Endovasc Surg
2014;48:421-7.
Objectives: International guidelines recommend supervised exercise
therapy (SET) as primary treatment for intermittent claudication (IC).
The aim of this study was to calculate treatment costs in patients with IC
and to estimate nationwide annual savings if a stepped care model (SCM,
primary SET treatment followed by revascularization in case of SET failure)
was followed.
Methods: Invoice data of all patients with IC in 2009 were obtained
from a Dutch health insurance company (3.4 million members). Patients
were divided into three groups based on initial treatment after diagnosis
(t0). The SET group received SET initiated at any time between 12 months
before and up to 3 months after t0. The intervention group (INT) under-
went endovascular or open revascularization between t0 and t+3 months.
The third group (REST) received neither SET nor any intervention. All pe-
ripheral arterial disease related invoices were recorded during 2 years and
average costs per patient were calculated. Savings following use of a SCM
were calculated for three scenarios.
Results: Data on 4954 patients were analyzed. Initial treatment
was SET (n = 701, 14.1%), INT (n = 1363, 27.5%), or REST (n =
2890, 58.3%). Within 2 years from t0, invasive revascularization in the
SET group was performed in 45 patients (6.4%). Additional interven-
tions (primary at other location and/or re-interventions) were per-
formed in 480 INT patients (35.2%). Some 431 REST patients
received additional SET (n = 299, 10.3%) or an intervention (n = 132,
4.5%). Mean total IC related costs per patient were V2,191, V9851
and V824 for SET, INT, and REST, respectively. Based on a hypothet-
ical worst, moderate, and best case scenario, some 3.8, 20.6, or 33.01097
